American BioMed Inc. Signs Distributor in France.

THE WOODLANDS, Texas--(BW HealthWire)--July 8, 1998--American BioMed Inc. (OTC BB:ABMI) Wednesday announced that Vitalitec International of Domalain, France, has been added to American BioMed's global distribution network.

Vitalitec, located in Domalain, is a major manufacturer and distributor to the French vascular surgery market.

Commenting for Vitalitec, Managing Director Jacques Le Bozec said, "We are most excited about promoting American BioMed products. With our vast experience in the vascular market, we should realize strong sales with their silicone catheter products." Vitalitec has placed initial stocking orders and training will begin this quarter.

Marshall Kerr, vice president of sales and marketing of American BioMed, stated: "The addition of Vitalitec brings us one step closer to realizing our goal of complete coverage for our products in the European marketplace. We will continue to search for quality distributors to expand our international network."

Steven B. Rash, president and CEO of American BioMed, said, "With the inclusion of Vitalitec, our market position significantly increases in Europe and is indicative of the strong worldwide interest in our latex-free silicone balloon catheters."

American BioMed has ten distributors covering the North American market and 16 international distributors covering Spain, Italy, Turkey, Australia, New Zealand, Belgium, Denmark, Greece, Japan, Luxembourg, The Netherlands, Norway, Sweden, Korea, Taiwan, India, the Caribbean, the United Kingdom and now, France.

American BioMed utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease.

The company's products include 100 percent-silicone catheters, through its Cathlab subsidiary; the Evert-O-Cath, a toposcopic catheter for site-specific drug delivery and fluid removal; the OmniCath, an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OrnniFilter, which is used to prevent blood clots from reaching various organs of the body.

The company has more than 25 patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive product development, commercialization and technological difficulties, the results of financing efforts, the effect of the company's accounting policies and other risks detailed in the company's Securities and Exchange Commission filings.

    CONTACT: American BioMed Inc., The Woodlands
              Steven B. Rash, 281/367-3895
                  or
              Coffin Communications, Sherman Oaks, Calif.
              Matt Lepo, 818/789-0100 (investor relations)
                  or
              Coffin-Mottola Communications, Irvine, Calif.
              Christi Mottola, 714/851-1109 (press relations)